Our Mission

PeopleBeatingCancer supports an evidence-based integrative approach to cancer care. For most newly diagnosed patients, FDA-approved therapies form the foundation of treatment, while evidence-based complementary therapies may help reduce side effects and improve survivorship.

Click the orange button to the right to learn more.

Curcumin and Drug-Resistant Lung Cancer: Can It Improve Chemotherapy Response?

Share Button

Curcumin and Drug-Resistant Lung Cancer: Can It Improve Chemotherapy Response? One of the major challenges in treating lung cancer is drug resistance.

A chemotherapy drug may initially kill or slow the growth of cancer cells, only for some cells to survive and eventually become less responsive to treatment. In some cases, cancer cells develop resistance to several different drugs—a phenomenon known as multidrug resistance (MDR).

This raises an important question:

Can anything make resistant lung cancer cells sensitive to chemotherapy again?

Curcumin—the best-known bioactive compound in turmeric—has attracted considerable research interest because laboratory studies suggest that it may affect several mechanisms involved in cancer growth and chemotherapy resistance.

Some studies involving lung cancer cells have found that curcumin can:

  • promote apoptosis, or programmed cancer-cell death;
  • influence signaling pathways associated with cancer survival;
  • increase the sensitivity of resistant lung cancer cells to chemotherapy;
  • affect microRNAs involved in drug resistance;
  • reduce cancer-cell proliferation, invasion, and migration.

That sounds promising.

But there is an important distinction every patient should understand:

Most of the evidence showing that curcumin can reverse chemotherapy resistance in lung cancer comes from laboratory studies—not clinical trials demonstrating that it improves survival in people with lung cancer.

That distinction changes how I think this research should be interpreted.

I am a long-term survivor of an incurable blood cancer called multiple myeloma.

Though I have been in complete remission from my blood cancer since 1999, I have spent a great deal of my time researching issues like reversing multi-drug resistance. I think that conventional oncology does a great job managing basic cancer treatments such as surgery, chemotherapy, radiation, immunotherapy, etc. so I choose to focus on evidence-based non-conventional therapies such as curcumin.

Like most topics on PeopleBeatingCancer.org, I believe that patient education is the key to managing a problem.

Scroll down and post a question or comment if there is anything you’d like to know about cancer and pain.

Good luck,

David Emerson


Concepts Central to Managing Your Cancer


Evidence-based, non-conventional lung cancer therapies:


What Is Multidrug Resistance in Lung Cancer?

Cancer is not a static disease.

Tumors contain populations of cells that can change and evolve under the selective pressure created by treatment. Cancer cells may develop mechanisms that allow them to survive drugs that previously worked.

Drug resistance can involve:

  • increased removal of chemotherapy drugs from cancer cells;
  • changes in the molecular targets of a drug;
  • enhanced DNA repair;
  • alterations in apoptosis pathways;
  • activation of alternative survival pathways;
  • changes in tumor metabolism;
  • genetic and epigenetic alterations;
  • changes in the tumor microenvironment.

A 2025 review in Nature Reviews Clinical Oncology describes multidrug resistance as an important continuing challenge in cancer treatment.

This is why researchers continue looking for compounds that might act as chemosensitizers—agents capable of making resistant cancer cells more susceptible to chemotherapy.

Curcumin is one of those compounds being investigated.


The Original Curcumin/Lung Cancer Study

The study that originally prompted me to write this article investigated curcumin in A549/DDP multidrug-resistant human lung adenocarcinoma cells.

Researchers found that curcumin promoted apoptosis in these chemotherapy-resistant cells.

They also discovered that curcumin altered microRNA activity, particularly a microRNA involved in regulating cancer-cell survival.

Research

Zhang J, et al. Curcumin promotes apoptosis in A549/DDP multidrug-resistant human lung adenocarcinoma cells through an miRNA signaling pathway.
Biochemical and Biophysical Research Communications. 2010.

PubMed:
https://pubmed.ncbi.nlm.nih.gov/20627087/

This is intriguing evidence because the experiment was specifically examining lung cancer cells that had developed multidrug resistance.

But it was a cell study.

It did not demonstrate that taking curcumin supplements reverses chemotherapy resistance in lung cancer patients.

That is an important limitation.


Curcumin and Paclitaxel-Resistant Lung Cancer

Another laboratory study investigated curcumin in paclitaxel-resistant non-small cell lung cancer (NSCLC) cells.

Paclitaxel is a chemotherapy drug used in the treatment of several cancers, including lung cancer.

Researchers reported that curcumin increased the sensitivity of resistant NSCLC cells to paclitaxel.

The proposed mechanism involved increased expression of microRNA-30c and decreased expression of metastasis-associated gene 1 (MTA1).

Research

Lu Y, et al. Curcumin increases the sensitivity of Paclitaxel-resistant NSCLC cells to Paclitaxel through microRNA-30c-mediated MTA1 reduction.
Tumour Biology. 2017.

PubMed:
https://pubmed.ncbi.nlm.nih.gov/28443468/

Again, this provides an interesting biological rationale for studying curcumin as a potential chemotherapy sensitizer.

It does not prove that curcumin supplementation improves chemotherapy response or survival in people with NSCLC.


How Might Curcumin Affect Cancer Cells?

Curcumin is particularly interesting because it does not appear to act on only one molecular target.

Preclinical research suggests that curcumin can influence pathways associated with:

  • apoptosis;
  • inflammation;
  • cellular proliferation;
  • angiogenesis;
  • invasion and metastasis;
  • PI3K/Akt signaling;
  • NF-κB signaling;
  • EGFR signaling;
  • cell-cycle regulation;
  • microRNA expression.

The National Cancer Institute notes that extensive laboratory research has found that curcuminoids interact with multiple signaling pathways involved in cancer development and progression.

Research

National Cancer Institute — Curcumin (Curcuma, Turmeric) and Cancer (PDQ)

https://www.cancer.gov/about-cancer/treatment/cam/patient/curcumin-pdq

That broad biological activity helps explain why curcumin has generated so much interest in cancer research.

It also illustrates one of the problems with translating laboratory curcumin research into clinical treatment.


The Curcumin Bioavailability Problem

Curcumin has notoriously poor oral bioavailability.

In other words, swallowing a curcumin supplement does not necessarily produce concentrations in human tumors comparable to the concentrations researchers use in laboratory experiments.

Curcumin is:

  • poorly absorbed;
  • rapidly metabolized;
  • rapidly eliminated.

Researchers have therefore developed formulations designed to improve absorption, including lipid-based preparations, phospholipid complexes and nanoparticle formulations.

Improved absorption does not automatically mean improved cancer outcomes, however.

The critical question remains:

Does an achievable concentration of curcumin in humans produce a clinically meaningful anticancer effect?

For lung cancer, we don’t yet have a definitive answer.


What Does Human Cancer Research Show?

This is where the evidence becomes much less certain.

Curcumin has been studied in patients with several cancers, both alone and in combination with conventional therapy. Some early trials have reported biological effects, acceptable tolerability or possible improvements in treatment-related symptoms.

But the studies have generally been small and have used different:

  • curcumin formulations;
  • dosages;
  • cancers;
  • stages of disease;
  • conventional treatments;
  • clinical endpoints.

A systematic review published in 2025 examined curcumin as a complementary therapy in oncology and found continuing interest in its potential benefits, but also substantial limitations in the available clinical evidence.

More importantly, the National Cancer Institute currently concludes that available clinical evidence is inadequate to recommend curcumin-containing products either as a cancer treatment or as an adjunct to conventional cancer treatment.

That is where I think the evidence needs to guide us.


PeopleBeatingCancer Evidence Rating

Question Evidence PBC Rating
Does curcumin affect lung cancer cells? Numerous laboratory studies Moderate preclinical evidence
Can curcumin trigger apoptosis in drug-resistant lung cancer cells? Laboratory studies Moderate preclinical evidence
Can curcumin resensitize paclitaxel-resistant NSCLC cells? Laboratory evidence Promising but preliminary
Does curcumin overcome chemotherapy resistance in lung cancer patients? Insufficient human clinical evidence Unproven
Does curcumin improve lung cancer survival? Insufficient clinical evidence Unproven
Is curcumin established as an FDA-approved lung cancer treatment? No No

How I interpret this evidence

Curcumin deserves continued investigation as a potential complementary cancer therapy and chemotherapy sensitizer.

But laboratory evidence should not be presented as clinical proof.

Curcumin has not been shown in well-designed human trials to reverse multidrug resistance or improve survival in lung cancer patients.


Curcumin Is Complementary—not a Replacement for Lung Cancer Treatment

This distinction is central to the PeopleBeatingCancer approach to integrative oncology.

Complementary therapies should complement appropriate cancer treatment—not automatically replace it.

Modern lung cancer treatment may include:

  • surgery;
  • radiation therapy;
  • chemotherapy;
  • immunotherapy;
  • targeted therapy;
  • combinations of these approaches.

The optimal treatment increasingly depends on the patient’s cancer type, stage and molecular characteristics.

If you are newly diagnosed, see:

Lung Cancer — What Patients Need to Know
https://peoplebeatingcancer.org/lung-cancer-need-to-know/

For a broader discussion of complementary strategies, see:

Integrative Lung Cancer Therapies
https://peoplebeatingcancer.org/integrative-lung-cancer-therapies/

And for my more comprehensive review of the curcumin evidence:

Lung Cancer and Curcumin: What the Science Says
https://peoplebeatingcancer.org/lung-cancer-and-curcumin/


What About Other Supplements and Integrative Therapies?

Curcumin is only one of many complementary approaches being studied in lung cancer.

Nutrition, exercise, maintaining muscle mass, smoking cessation, management of vitamin deficiencies and treatment of side effects can all be important parts of comprehensive cancer care.

See:

Supplementation for Lung Cancer Patients
https://peoplebeatingcancer.org/supplementation-for-lung-cancer-patients/

Patients dealing with treatment-related or cancer-related pain may also want to read:

Lung Cancer and Pain: What Patients and Survivors Need to Know
https://peoplebeatingcancer.org/lung-cancer-and-pain-what-patients-and-survivors-need-to-know/


Can Curcumin Interact With Cancer Treatment?

Yes, potentially.

This is another reason I would not recommend simply adding high-dose curcumin to a chemotherapy regimen without discussing it with the oncology team.

Memorial Sloan Kettering Cancer Center lists potential interactions between turmeric/curcumin and several medications. Turmeric may also increase bleeding risk in people taking anticoagulant or antiplatelet medications.

There have also been reports of liver injury associated with some curcumin-containing supplements.


Research

Memorial Sloan Kettering Cancer Center — Turmeric

https://www.mskcc.org/cancer-care/integrative-medicine/herbs/turmeric

National Cancer Institute — Curcumin and Cancer

https://www.cancer.gov/about-cancer/treatment/cam/hp/curcumin-pdq

Cancer patients should therefore tell their oncologist, pharmacist or integrative oncology specialist about every supplement they take, including turmeric and curcumin.


My Perspective as a Long-Term Cancer Survivor

I am a long-term survivor of multiple myeloma—not lung cancer.

My experience taught me to look beyond the simple question:

Does this therapy cure cancer?

I think a better series of questions is:

  • What does the evidence actually show?
  • Is the evidence laboratory, animal or human evidence?
  • Could the therapy complement conventional treatment?
  • Could it reduce treatment toxicity or improve quality of life?
  • Could it interact with chemotherapy or other medications?
  • What don’t we know yet?

I have used evidence-based complementary therapies as part of my own long-term survivorship strategy.

But personal experience isn’t the same thing as clinical evidence.

That distinction is especially important with curcumin.

The laboratory evidence surrounding curcumin and cancer is extensive and biologically interesting. The human evidence is much less developed.


The Bottom Line

Can curcumin overcome multidrug resistance in lung cancer?

In laboratory models, there is evidence suggesting that it can affect mechanisms of drug resistance and make certain chemotherapy-resistant lung cancer cells more sensitive to treatment.

In people with lung cancer, however, we do not yet have convincing clinical evidence demonstrating that curcumin reverses chemotherapy resistance or improves survival.

That makes curcumin an interesting investigational complementary therapy, not a proven treatment for drug-resistant lung cancer.

For patients considering curcumin during chemotherapy, the most reasonable approach is to:

  1. understand exactly which lung cancer subtype you have;
  2. identify the chemotherapy, targeted therapy or immunotherapy you are receiving;
  3. review potential supplement-drug interactions;
  4. discuss curcumin with your oncologist or oncology pharmacist;
  5. treat curcumin as complementary rather than as a replacement for evidence-based cancer treatment.

The science is worth following.

But the evidence isn’t yet strong enough to make the leap from “curcumin affects chemotherapy-resistant lung cancer cells” to “curcumin overcomes chemotherapy resistance in lung cancer patients.”

That difference matters.

If you have lung cancer and are considering curcumin or another complementary therapy, leave a question or comment below. Tell me your lung cancer type, stage and treatment regimen, and I will help you research the evidence.


Research

National Cancer Institute. Curcumin (Curcuma, Turmeric) and Cancer (PDQ®).
https://www.cancer.gov/about-cancer/treatment/cam/hp/curcumin-pdq

Zhang J, et al. Curcumin promotes apoptosis in A549/DDP multidrug-resistant human lung adenocarcinoma cells through an miRNA signaling pathway. Biochem Biophys Res Commun. 2010.
https://pubmed.ncbi.nlm.nih.gov/20627087/

Lu Y, et al. Curcumin increases the sensitivity of Paclitaxel-resistant NSCLC cells to Paclitaxel through microRNA-30c-mediated MTA1 reduction. Tumour Biology. 2017.
https://pubmed.ncbi.nlm.nih.gov/28443468/

Gutsche LC, Dörfler J, Hübner J. Curcumin as a complementary treatment in oncological therapy: a systematic review. European Journal of Clinical Pharmacology. 2025.

Ge M, et al. Understanding and overcoming multidrug resistance in cancer. Nature Reviews Clinical Oncology.2025.

Memorial Sloan Kettering Cancer Center. Turmeric.
https://www.mskcc.org/cancer-care/integrative-medicine/herbs/turmeric

Curcumin Drug-Resistant Lung Cancer

Curcumin Drug-Resistant Lung Cancer

Curcumin Drug-Resistant Lung Cancer

Leave a Comment:

6 comments
Vitamin D, Pulmonary Inflammation and Lung Cancer - PeopleBeatingCancer says 3 years ago

[…] Curcumin, Integrative Therapies, Can Overcome Multidrug-Resistance In LC […]

Reply
Vitamin B Serum Blood Levels as Lung Cancer Therapy - PeopleBeatingCancer says 7 years ago

[…] Curcumin, Integrative Therapies, Can Overcome Multidrug-Resistance In Lung Cancer […]

Reply
Metformin Improves Lung Cancer Survival by 66% - PeopleBeatingCancer says 8 years ago

[…] Curcumin, Integrative Therapies, Can Overcome Multidrug-Resistance In LC […]

Reply
Early Lung Cancer Therapies Reduce Cancer Deaths Significantly - PeopleBeatingCancer says 8 years ago

[…] Curcumin, Integrative Therapies, Can Overcome Multidrug-Resistance In Lung Cancer […]

Reply
Asthma Linked to Lung Cancer Risk in Study - PeopleBeatingCancer says 8 years ago

[…] Curcumin, Integrative Therapies, Can Overcome Multidrug-Resistance In Lung Cancer […]

Reply
Lung Cancer Chemo and Radiation Synergy Enhances Overall Survival- PeopleBeatingCancer says 8 years ago

[…] Curcumin, Integrative Therapies, Can Overcome Multidrug-Resistance In Lung Cancer […]

Reply
Add Your Reply